Ladies and gentlemen,

Please find enclosed two new papers and a poster dealing with the PLT VASP/P2Y12 kit (7014).

  • "Comparison of platelet P2Y12 ADP receptor mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP phosphorylation in japanese patients undergoing coronary stenting " Fu Q., et al. , Int Heart J 2010, 51, 303-307.

    Clopidogrel plus cilostazol is more effective in inhibiting the platelet P2Y(12) ADP receptor pathway than clopidogrel alone. This may be useful for reducing clopidogrel resistance in Japanese patients.

  • First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel. The ONSET/OFFSET and RESPOND genotype studies. Tantry U et al., Circ Cardiovasc Genet 2010, in press .

    This report is the first to demonstrate the superior pharmacodynamic effect of ticagrelor compared with clopidogrel irrespective of CYP2C19 genotype.

  • Also one poster from the AHA meeting: Patients with the CYP2C19 *2 allelic variant show significantly higher platelet activation in the VASP assay. Clopidogrel non-responders identified by VASP might be candidates for further genetic testing.

    Conclusion: The prediction of platelet activation by CYP2C19 *2 carrier status varies between different platelet function tests, being most pronounced when assessed by the VASP test.

MILAN ANALYTICA is the exclusive Swiss distributor for BioCytex products (monoclonal antibodies against CD markers and kits for platelet diagnosis).

Please do not hesitate to contact us for further information.

Thank you for your attention and best regards

Julia Hirtle
Sales and Marketing Manager Distribution

Baslerstrasse 15
4310 Rheinfelden/Basel

fon +41 (0)61 845 99 88
fax +41 (0)61 845 99 87

  MILAN ANALYTICA AG • 4310 Rheinfelden • Switzerland • phone 0041 61 845 99 88
  If you do not want to receive such information, please send an e-mail to